Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adjustable Continence Therapy for Women | Experimental | Implantation of the Adjustable Continence Therapy for the treatment of female SUI. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Adjustable Continence Therapy for Women (ACT) | Device | Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately). |
| Measure | Description | Time Frame |
|---|---|---|
| Provocative pad weight | Change in provocative pad weight from baseline | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Urogenital Distress Inventory (UDI) | Six item questionnaire. Scores range from 0-100. 0 being not distressed, 100 being very distressed. | 12 months |
| Incontinence Quality of Life Questionnaire (I-QOL) |
| Measure | Description | Time Frame |
|---|---|---|
| Complete adverse event profile | Collection of patient safety information | 12 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lisa Draper | Contact | 612-834-7494 | USLDR@COLOPLAST.COM | |
| Matt Kelly, PhD | Contact | 612-469-8882 | usmtk@coloplast.com |
| Name | Affiliation | Role |
|---|---|---|
| Philip Johnson, PhD | Uromedica, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Colorado | Recruiting | Denver | Colorado | 80045 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D014550 | Urinary Incontinence, Stress |
| D014555 | Urination Disorders |
| D053206 | Nocturnal Enuresis |
| D014570 | Urologic Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| ID | Term |
|---|---|
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
A prospective, single arm, non-randomized, multicenter, prospective case-series trial.
Not provided
Not provided
Not provided
Not provided
|
Twenty-two item questionnaire. Scores range from 0-100. 0 being lowest quality of life, 100 being highest quality of life.
| 12 months |
| CHI Health Research Center | Recruiting | Omaha | Nebraska | 68124 | United States |
|
| Hôpital de la Conception - Marseille | Recruiting | Marseille | 13005 | France |
|
| CHU de Nantes | Recruiting | Nantes | 44000 | France |
|
| Pitié Salpêtrière University Hospital Paris | Recruiting | Paris | 75013 | France |
|
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D004775 | Enuresis |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D019960 | Elimination Disorders |
| D001523 | Mental Disorders |